Arvinas (ARVN)
(Delayed Data from NSDQ)
$35.95 USD
+1.30 (3.75%)
Updated May 22, 2024 04:00 PM ET
After-Market: $35.96 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Arvinas, Inc. [ARVN]
Reports for Purchase
Showing records 21 - 40 ( 204 total )
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Bevdeg Makes Way for ARV-766; Upgrading to OUTPERFORM
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ARV-471 Palbociclib Combination Might Be Superior To SOC-Our Thoughts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Ph 3 VERITAC-2 and 3 Trials Officially Underway
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ARV-766 Shows Potential Against Multiple AR Mutants, Though Data is Early
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Our Insights on the ARV-471''s Phase 1b/2 Combo Trial Update; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ASCO 2023 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Roundup for 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - Roundup For 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Alignment on 1L ARV-471 + Palbo Ph 3
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on Dose Selection for First-Line Phase 3 Combo Trial with Palbociclib; Reit. Buy and $90 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Frontline Ph 3 Delay with Study Amendment; PT to $27
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R